Compugen Ltd. has reported its financial results for the third quarter of 2026, revealing a notable increase in revenue and significant progress in its clinical trials. The company, which specializes in cancer immunotherapy and computational drug target discovery, continues to advance its pipeline and is optimistic about upcoming results.

On November 9, 2026, Compugen issued a press release detailing its third quarter results, marking a pivotal moment for the company. The report highlights that Compugen is on track to deliver results from its MAIA-ovarian trial by the end of the first quarter of 2027, a key study evaluating its anti-PVRIG antibody, COM701. This trial is crucial as it addresses a significant unmet need in the treatment of relapsed platinum-sensitive ovarian cancer.

Background

Compugen Ltd. is a clinical-stage therapeutic discovery and development company based in Holon, Israel. It operates under the Standard Industrial Classification (SIC) code 2836, which pertains to Biological Products (No Diagnostic Substances). The company is publicly traded on the Nasdaq under the ticker CGEN and is recognized for its innovative use of artificial intelligence in drug discovery.

What the Filing Says

The filing indicates that Compugen's revenues for the third quarter of 2026 reached approximately $3.8 million, a significant increase from about $1.9 million in the same period of 2025. This growth is attributed to the recognition of payments under its licensing agreement with Gilead. The company also reported a net loss of approximately $5.8 million, down from $7.0 million in the third quarter of the previous year.

In the press release, Dr. Eran Ophir, President and CEO of Compugen, stated, "During the third quarter, we continued to advance COM701 and GS-0321 in the clinic, as well as build the next generation of our pipeline. We remain on track to report results by the end of the first quarter of 2027."

Impact

This financial update is significant not only for Compugen but also for the broader biological products industry. The advancements in Compugen's pipeline, particularly in cancer immunotherapy, may influence other companies in the sector to accelerate their research and development efforts. Compugen's collaborations with AstraZeneca and Gilead further position it as a competitive player in the market.

What's Next

Looking ahead, Compugen plans to hold a conference call on November 9, 2026, to discuss its third quarter results in detail. The company is expected to continue its focus on delivering results from its ongoing clinical trials, particularly the MAIA-ovarian study and the ARTEMIDE-Biliary01 trial, which will provide critical data in 2027. The filing does not specify any additional immediate actions beyond these updates.